Navigation Links
Wyeth Provides Regulatory Update on Prevnar 13* in the United States
Date:8/11/2009

sible for the greatest remaining burden of invasive disease. Prevnar has been available in the U.S. for more than nine years. It is currently available in 95 countries and more than 235 million doses have been distributed worldwide.

The Prevnar 13 submission is based on a clinical trial program of 13 core Phase 3 studies involving more than 7,000 infants and young children. To date, the company has submitted regulatory applications for Prevnar 13 in more than 50 countries spanning six continents, with filings in additional countries planned. In July, Prevenar 13*, as it is known outside the U.S., was approved in Chile for use in infants and young children.

About Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease is the leading cause of vaccine-preventable death worldwide in children younger than 5 years of age and is estimated to cause up to one million deaths worldwide in children each year.

Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media.

Important Safety Information for Prevnar 13*

In clinical studies, the most commonly reported adverse events in children were injection site reactions, fever, irritability, decreased appetite, and increased and/or decreased sleep. Risks are associated with all vaccines, including Prevnar 13. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. As with any vaccine, Prevnar 13 may not provide 100% protection against vaccine serotypes or protect against nonvaccine serotypes.

Indication for Prevnar((R))

Prevnar(R) is indicated for act
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Wyeth Announces Holder Right to Surrender Convertible Debentures
4. Wyeth Declares Common Stock Dividend
5. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
6. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
7. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
8. Wyeth Declares Common and Preferred Stock Dividends
9. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
10. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
11. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Bill Jacobs Automotive, a group of car dealerships ... with the Heartland Blood Center and offering free oil change ... takes place Saturday, Jan. 18 at the Bill Jacobs Cadillac ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... forum for the global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle ... ... DUBAI, United Arab Emirates, Sept. 4 The Middle East,market for pharmaceutical ... growth in double digits. The market,drivers are: -- Dubai is the ...
... Monitoring Versus Implementing Changes to Lower ... A recent survey of U.S.,adults with high ... the,serious health risks associated with their condition, such ... is a significant disconnect,between understanding what should be ...
... Sept. 4 Volcano,Corporation (Nasdaq: VOLC ), ... (FM) products designed to enhance the diagnosis,and treatment ... that it,will be participating in the Bear Stearns ... presentation by Scott Huennekens, president and chief executive,officer, ...
Cached Biology Technology:New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 2New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 3New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 4New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 5New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 6New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 7Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2
(Date:4/18/2014)... wildlife while feeding a world population predicted to ... holistic approach to conservation that considers human-altered landscapes ... Wildlife and the natural habitat that supports it ... world where at least three-quarters of the land ... rest is vulnerable to human-caused impacts such as ...
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may ... to be more careful. In the wild, a plant whose ... would risk disaster. More than just an insurance policy against ... seed dormancy has long-term advantages too: Plants whose seeds ... to more species, finds in a team of researchers working ...
(Date:4/17/2014)... COLUMBIA, Mo. April 17 In the most densely ... States, forests reflect two centuries of human needs, values ... logging and clearing forests for agriculture and development, have ... today, a U.S. Forest Service study reports. , The ... forest conditions and management needs in the Northern United ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... wetlands are vital to the water cycle and ... GlobWetland, an ESA-led initiative in collaboration with the ... by using satellite imagery to provide detailed wide-area ... local conservation efforts. , Because the success of ...
... bacterial surface proteins that generate the strongest immune ... Chicago have created a vaccine that significantly protects ... Staphylococcus aureus, the most common cause of hospital-acquired ... illness. , The vaccine protected mice against ...
... an experimental targeted therapy with a common anti-inflammatory ... cancer, researchers at UCLA's Jonsson Cancer Center reported. ... anti-inflammatory drug Celebrex increased response rates in lung ... Reckamp, an assistant professor of hematology/oncology and lead ...
Cached Biology News:African wetland managers armed with new technology 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Combination therapy shows promising results in patients with advanced lung cancer 2Combination therapy shows promising results in patients with advanced lung cancer 3
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
Epstein-Barr Virus (EBV) (EBNA-1)...
ECE-1 (H-60)...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: